![]() The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. MindMed is a clinical-stage biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address mental health and addiction. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. To learn more about Novamind's clinical research division, visit this link. The LSD Clinical Trial is expected to move through a series of key milestones over the coming months to prepare for enrollment and patient dosing. Our team continues to build on Novamind's reputation as an industry leader in clinical research for psychedelic medicine, and we are proud to be a trusted partner for this important work." Yaron Conforti, CEO and Director, Novamind, commented, "We're excited to host MindMed's historic clinical trial, and to contribute to advancing LSD towards FDA approval. Working with companies like Novamind who have experience running clinical research sites for Schedule I substances will be critical to the quality and success of this trial." Jamie Freedman, Director of Clinical Operations, MindMed, said: "We're pleased to have finalized our site selection process. ![]() "We're honored to participate in this research study involving such a long-awaited therapy with potential to transform the treatment paradigm in anxiety." Reid Robison, Chief Medical Officer, Novamind. "With anxiety disorders being among the most common mental health conditions, there's a pressing need for new treatment options and, in particular, medications with novel mechanisms of action like LSD," said Dr. Novamind expects to add LSD under the licenses in relation to the LSD Clinical Trial. In October 2021, Novamind was awarded two DEA Schedule 1 licenses for psilocybin research, qualifying it to conduct a recently announced phase II trial for major depressive disorder sponsored by the Usona Institute, as well as future psilocybin trials. Novamind will host the LSD Clinical Trial at its Draper, Utah research site, further strengthening its track record of hosting neuropsychiatry and psychedelic clinical trials. The multi-site LSD Clinical Trial plans to enroll 200 participants with dosing expected later this year. The primary objective of the study is to determine the reduction in anxiety symptoms for up to twelve weeks after a single administration of MindMed's proprietary drug candidate, MM-120, a pharmacologically optimized form of LSD being developed for GAD and other brain-based disorders. The LSD Clinical Trial is the most advanced program in MindMed's clinical drug development pipeline and is the first commercial study of LSD in over 40 years. MindMed is a clinical-stage biotech company developing the next generation of psychedelic-inspired medicines and therapies. (NASDAQ:MNMD), (NEO:MMED) ("MindMed") to host a phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder (GAD) in adults ("LSD Clinical Trial"). (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce it has been selected by Mind Medicine, Inc. TORONTO, ON / ACCESSWIRE / Ma/ Novamind Inc.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |